Results of the treatment of a total of 38 patients with stage I-IIIA Hodgkin's disease, who had been treated at Department of Radiation Oncology, Yonsei Cancer Center form July 1980 to June 1988, were analyzed retrospectively.
Staging laparotomy was done in 7 patients, and the majority of cases were classified by clinical staging(Ann Arbor System: stage IA: 9, IB: 3, IIA: 11, IIB: 7, IIIA: 8).
Twenty one patients were treated with radiotherapy alone and 17 with combined modality (chemotherapy + radiotherapy). There were complete responses in 35 of 38 cases(92%). Nine patients developed relapsing Hodgkin's disease, and salvage therapy
was
successful in 64% of relapsing patients. The overall 5 year actuarial rate and the 5 year relapse free survival rate were 69% and 47%, respectively, Regardless of treatment modality, 5 year actuarial survival rates of stage I, II and IIIA were
91%,
63%
and 43%, respectively.
There was no significant difference of 5 year survival rates between radiotherapy alone and combined modality in patients with stage I and IIA Hodgkin's disease(87% vs 85%). The 5 year survival rates in patients with stage IIB and IIIA Hodgkin's
disease
who had been treated radiotherapy alone or combined modality was 53% and 14% respectively. There was a trend toward increasing survival with combined modality in stage IIB and IIIA Hodgkin's disease while this difference was not statistically
significant with the small number of cases involved in this study.
We noted that favorable prognostic factors in stage I-IIIA Hodgkin's disease were younger age(less than 30 years old), histology(lymphocyte predominance or nodular sclerosis) and earlier stage.
It was difficult to evaluate complications and second malignancies following treatment due to the rather short period of follow-up. Therefore, long-term follow-up is essential to identify complications of treatment.
|